By Clinical Research News Staff 

January 11, 20202 | Parexel today announced the completion of the separation of its Parexel Informatics and Medical Imaging business from the parent company. The strategic move is designed to simplify and streamline Parexel’s business strategy and customer relationships while best positioning both organizations for continued, long-term growth and success. 

Parexel Informatics becomes Calyx, a provider of medical imaging, eClinical, and regulatory solutions and services to solve complex challenges in clinical research. 

“Today our industry needs to move at a 21st century pace and Calyx, as an independent company, is focused on enabling global biopharmaceutical customers and clinical research organizations (CROs) to leverage innovative technology solutions and services in the pursuit of cures,” said Gavin Nichols, Chief Executive Officer at Calyx in a statement. “While the name is new, Calyx has a long history of solving complex problems to accelerate new product development—from selecting the right biomarker in early stage imaging to the electronic management of entire global development programs. We’re excited about this next stage of our journey.”

With 250 new drug approvals in its history, the group that is now Calyx has supported over 25,000 trials involving more than fourteen million patients. The company will continue its focus on providing innovative technology solutions and services to speed the discovery of new treatments, according to the statement. 

Parexel will continue to leverage Calyx’s Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), Interactive Response Technology (IRT) and Regulatory Information Management (RIM) solutions moving forward as part of the company’s clinical development offerings. 

"Today's announcement marks a significant milestone as we further position Parexel to expect accelerated growth and performance as a top-tier CRO," said Jamie Macdonald, Chief Executive Officer of Parexel in a separate statement. "We believe the separation will provide Calyx the opportunity to prioritize investments in technology development, customer delivery and customer relationships while enabling the Parexel corporate business to strengthen its focus on the delivery of innovative clinical development solutions that reinforce our patients-first focus and advance world health.”

Calyx will be led by Chief Executive Officer Gavin Nichols and the company will be headquartered in Nottingham, United Kingdom, and Durham, North Carolina. The new organization will employ approximately 2,300 employees. Calyx will be privately held by the same ownership group that has owned Parexel since 2017.